Patient-Derived Organoids as a Promising Tool for Multimodal Management of Sarcomas

Abstract

The management of sarcomas, a diverse group of cancers arising from connective tissues, presents significant challenges due to their heterogeneity and limited treatment options. Patient-derived sarcoma organoids (PDSOs) have emerged as a promising tool in the multimodal management of sarcomas, offering unprecedented opportunities for personalized medicine and improved treatment strategies. This review aims to explore the potential of PDSOs as a promising tool for multimodal management of sarcomas. We discuss the establishment and characterization of PDSOs, which realistically recapitulate the complexity and heterogeneity of the original tumor, providing a platform for genetic and molecular fidelity, histological resemblance, and functional characterization. Additionally, we discuss the applications of PDSOs in pathological and genetic evaluation, treatment screening and development, and personalized multimodal management. One significant advancement of PDSOs lies in their ability to guide personalized treatment decisions, enabling clinicians to assess the response and efficacy of different therapies in a patient-specific manner. Through continued research and development, PDSOs hold the potential to revolutionize sarcoma management and drive advancements in personalized medicine, biomarker discovery, preclinical modeling, and therapy optimization. The integration of PDSOs into clinical practice can ultimately improve patient outcomes and significantly impact the field of sarcoma treatment.

Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance

“…Integrating advanced strategies that account for drug-induced resistance with conventional cancer therapies represents a significant step toward a new era in cancer treatment. This multifaceted approach emphasizes the need for continuous research and adaptation to refine immunotherapy regimens, ensuring they remain potent against cancer while respecting the patient's overall well-being and minimizing unintended resistance [17,123].…”

“…Precision medicine plays a crucial role in this, with targeted therapies designed to counteract specific pathways of resistance identified in a patient's tumor profile [17]. Adopting personalized treatment regimens based on molecular diagnostics and patientderived models, such as organoids and xenografts, is showing promise in enhancing treatment efficacy and reducing toxicity [123]. Furthermore, the implementation of realtime monitoring systems and predictive biomarkers facilitates a more responsive approach to immunotherapy adjustments [124,125].…”